At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMLX Amylyx Pharmaceuticals
Post-Mkt 05-27 19:23:45 EDT
14.07
+0.39
+2.85%
盘后14.07
+0.000.00%
17:06 EDT
High14.25Low13.74Vol580.25K
Open13.91D1 Closing13.68Amplitude3.69%
Mkt Cap1.56BTradable Cap920.87MTotal Shares111.19M
T/O8.16MT/O Rate0.89%Tradable Shares65.45M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Amylyx director Karen Firestone acquires $51,338 of common shares
Reuters  ·  05-27 04:00
Amylyx director Karen Firestone acquires $51,338 of common shares
Do HELIOS Data Shift Amylyx (AMLX) From ALS Setback To Broader Rare-Disease Strategy Reboot?
Simply Wall St.  ·  05-22
Do HELIOS Data Shift Amylyx (AMLX) From ALS Setback To Broader Rare-Disease Strategy Reboot?
Amylyx announces publication of Phase 2 open-label HELIOS trial data
TIPRANKS  ·  05-16
Amylyx announces publication of Phase 2 open-label HELIOS trial data
Amylyx posts Phase 2 HELIOS data showing AMX0035 benefits in Wolfram syndrome
Reuters  ·  05-16
Amylyx posts Phase 2 HELIOS data showing AMX0035 benefits in Wolfram syndrome
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label Helios Trial Data for Amx0035 in the Journal of Clinical Investigation
THOMSON REUTERS  ·  05-16
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label Helios Trial Data for Amx0035 in the Journal of Clinical Investigation
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  05-11
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)
TIPRANKS  ·  05-10
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)
Stock Track | Amylyx Pharmaceuticals Plummets 8.16% Intraday on Wider-Than-Expected Q1 Loss
Stock Track  ·  05-08
Stock Track | Amylyx Pharmaceuticals Plummets 8.16% Intraday on Wider-Than-Expected Q1 Loss
Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-08
Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Amylyx Pharmaceuticals Q1 net loss widens more than expected on higher R&D costs
Reuters  ·  05-07
Amylyx Pharmaceuticals Q1 net loss widens more than expected on higher R&D costs
Earnings Flash (AMLX) Amylyx Posts Q1 Loss $0.37 a Share, vs. FactSet Est of $0.35 Loss
MT Newswires Live  ·  05-07
Earnings Flash (AMLX) Amylyx Posts Q1 Loss $0.37 a Share, vs. FactSet Est of $0.35 Loss
Amylyx Pharma Q1 EPS $(0.37), Inline, Cash, Cash Equivalents, And Short-Term Investments Were $279.8M, With Expected Cash Runway into 2028
Benzinga  ·  05-07
Amylyx Pharma Q1 EPS $(0.37), Inline, Cash, Cash Equivalents, And Short-Term Investments Were $279.8M, With Expected Cash Runway into 2028
Amylyx Q1 net loss widens to $41.3 million
Reuters  ·  05-07
Amylyx Q1 net loss widens to $41.3 million
BRIEF-Amylyx Pharmaceuticals Q1 EPS USD -0.37 Vs. IBES Estimate USD -0.33
Reuters  ·  05-07
BRIEF-Amylyx Pharmaceuticals Q1 EPS USD -0.37 Vs. IBES Estimate USD -0.33
Amylyx Pharmaceuticals Inc - Cash Runway Expected to Fund Operations Into 2028
THOMSON REUTERS  ·  05-07
Amylyx Pharmaceuticals Inc - Cash Runway Expected to Fund Operations Into 2028
Press Release: Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
Dow Jones  ·  05-07
Press Release: Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  05-07
Calendar of U.S. Earnings Expected in the Week Ahead
Amylyx management participates in Bank of America Health Care Conference fireside chat
Reuters  ·  05-06
Amylyx management participates in Bank of America Health Care Conference fireside chat
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults With Post-Bariatric Hypoglycemia
THOMSON REUTERS  ·  05-05
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults With Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals Inc - Avexitide Phase 3 Lucidity Trial Topline Data Readout Anticipated in Q3 2026
THOMSON REUTERS  ·  05-05
Amylyx Pharmaceuticals Inc - Avexitide Phase 3 Lucidity Trial Topline Data Readout Anticipated in Q3 2026

Introduction

Company Name.
Amylyx Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Issue price:
--